» Articles » PMID: 30206801

Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease

Overview
Journal Drugs
Specialty Pharmacology
Date 2018 Sep 13
PMID 30206801
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Pain is one of the most common symptoms among patients with end-stage renal disease (ESRD), and is often under recognized and not adequately managed in hemodialysis (HD) patients. Barriers to adequate pain management include poor awareness of the problem, insufficient medical education, fears of possible drug-related side effects, and common misconceptions about the inevitability of pain in elderly and HD patients. Caregivers working in HD should be aware of the possible consequences of inadequate pain assessment and management. Common pain syndromes in HD patients include musculoskeletal diseases and metabolic neuropathies, associated with typical intradialytic pain. Evaluating the etiology, nature, and intensity of pain is crucial for choosing the correct analgesic. A mechanism-based approach to pain management may result in a better outcome. Pharmacokinetic considerations on clearance alterations and possible toxicity in patients with ESRD should drive the right analgesic prescription. Comorbidities and polymedications may increase the risk of drug-drug interactions, therefore drug metabolism should be taken into account when selecting analgesic drugs. Automedication is common among HD patients but should be avoided to reduce the risk of hazardous drug administration. Further research is warranted to define the efficacy and safety of analgesic drugs and techniques in the context of patients with ESRD as generalizing information from studies conducted in the general population could be inappropriate and potentially dangerous. A multidisciplinary approach is recommended for the management of complex pain syndromes in frail patients, such as those suffering from ESRD.

Citing Articles

Bio-sociological and clinical factors of chronic pain and pain interference in patients undergoing hemodialysis: a cross-sectional study.

Bouchachi F, Wachami N, Iderdar Y, Arraji M, Elgot A, Chahboune M BMC Nephrol. 2025; 26(1):83.

PMID: 39966760 PMC: 11834491. DOI: 10.1186/s12882-025-03987-7.


The Challenge of Managing Neuropathic Pain in Children and Adolescents with Cancer.

Coluzzi F, Stefano G, Scerpa M, Rocco M, Di Nardo G, Innocenti A Cancers (Basel). 2025; 17(3).

PMID: 39941827 PMC: 11816330. DOI: 10.3390/cancers17030460.


Pain Assessment in Patients during Hemodialysis Treatment: Quality Improvement Project.

Rodrigues R, Costeira C Nurs Rep. 2024; 14(2):1370-1387.

PMID: 38921713 PMC: 11206322. DOI: 10.3390/nursrep14020103.


To Be Frail or Not to Be Frail: This Is the Question-A Critical Narrative Review of Frailty.

Sciacchitano S, Carola V, Nicolais G, Sciacchitano S, Napoli C, Mancini R J Clin Med. 2024; 13(3).

PMID: 38337415 PMC: 10856357. DOI: 10.3390/jcm13030721.


New Perspectives on the Adverse Effects of NSAIDs in Cancer Pain: An Italian Delphi Study from the Rational Use of Analgesics (RUA) Group.

Varrassi G, Coluzzi F, Fornasari D, Fusco F, Gianni W, Guardamagna V J Clin Med. 2022; 11(24).

PMID: 36556066 PMC: 9781542. DOI: 10.3390/jcm11247451.


References
1.
Goksan B, Karaali-Savrun F, Ertan S, Savrun M . Haemodialysis-related headache. Cephalalgia. 2004; 24(4):284-7. DOI: 10.1111/j.1468-2982.2004.00668.x. View

2.
Sommer C, Cruccu G . Topical Treatment of Peripheral Neuropathic Pain: Applying the Evidence. J Pain Symptom Manage. 2017; 53(3):614-629. DOI: 10.1016/j.jpainsymman.2016.09.015. View

3.
Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J . Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005; 114(1-2):29-36. DOI: 10.1016/j.pain.2004.12.010. View

4.
Leonard C, Freeman C, Newcomb C, Reese P, Herlim M, Bilker W . Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012; 21(11):1155-72. DOI: 10.1002/pds.3329. View

5.
Kroenke K, Spitzer R, Williams J . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-13. PMC: 1495268. DOI: 10.1046/j.1525-1497.2001.016009606.x. View